A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

LONDON, Feb 4 (Reuters) - European mobile group Vodafone (VOD.L), opens new tab reported another deterioration in Germany, its biggest market, in its third quarter, a weak point amid otherwise ...

FLENSBURG, Germany — Friedrich Merz is Germany’s likely next chancellor, but how he will form a coalition government is looking increasingly uncertain. At a campaign event on Friday in the northern ...

A ~$4.5B share repurchase program adds further value. LIBTAYO demonstrated massive growth, accelerating to 50% in Q4 2024 versus Q4 2023. Approval in CSCC means that this growth catalyst is ...

Germany's leading source of electric power generation got a big boost in 2024, according to latest industry figures. Regulators approved more than 2,400 new onshore wind turbines with a total ...

Investing.com - European stock markets edged higher Friday, with investors digesting more corporate earnings as well as regional inflation data after the European Central Bank’s latest easing of ...

In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...

The trial evaluates THIO's safety, tolerability, and efficacy in combination with PD-(L)1 inhibition. THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who ...